Anacetrapib: Difference between revisions
Jump to navigation
Jump to search
imported>Daniel Mietchen m ({{subpages}}) |
imported>David E. Volk (Chemical structure drawing inserted) |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
{{Image|Anacetrapib.png|right|200px|Chemical Structure of Anacetrapib.}} | |||
In [[health care]], '''anacetrapib''' (anacet'rapib) is an oxazolidinone [[medication]] that is a cholesteryl ester transfer protein inhibitor that raises [[HDL cholesterol]] and reduces [[LDL cholesterol]].<ref>{{MeSH}}</ref> | In [[health care]], '''anacetrapib''' (anacet'rapib) is an oxazolidinone [[medication]] that is a cholesteryl ester transfer protein inhibitor that raises [[HDL cholesterol]] and reduces [[LDL cholesterol]].<ref>{{MeSH}}</ref> | ||
Revision as of 09:00, 26 November 2010
In health care, anacetrapib (anacet'rapib) is an oxazolidinone medication that is a cholesteryl ester transfer protein inhibitor that raises HDL cholesterol and reduces LDL cholesterol.[1]
Anacetrapib is related to torcetrapib.[2]
References
- ↑ Anonymous (2024), Anacetrapib (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM et al. (2010). "Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.". N Engl J Med. DOI:10.1056/NEJMoa1009744. PMID 21082868. Research Blogging.